Bespak Announces Spin-Out from Recipharm, Focusing on Greener Inhalers

Bespak has completed the transaction to become a standalone company, separating from the Recipharm Group. This move creates a leading global contract development and manufacturing organisation (CDMO) dedicated to the development of drug-delivery devices for pulmonary and nasal inhalation, backed by EQT Private Equity. Integrating three sites, Bespak now expands its reach in delivering pressurised Metered Dose Inhaler (pMDI) dosing valves, actuators, and complex Dry Powder Inhaler (DPI) devices.

Chris Hirst, previously with Recipharm, steps in as the CEO of this newly independent entity, aimed at becoming an innovation partner in the move towards more sustainable inhalers. The company anticipates a significant role in the transition to low Global Warming Potential (GWP) propellants, marked by a notable investment at its Holmes Chapel site for enhanced manufacturing capabilities.

The recent investment will facilitate the manufacture of pMDIs using HFA-152a, catering to the demand for greener propellants. This follows a significant milestone where the site became the first CDMO to produce a commercial-scale pMDI using HFO-1234ze, a propellant with a near-zero GWP. Bespak's commitment to sustainability and innovation positions it uniquely in the market, fulfilling evolving pharmaceutical needs while ensuring environmental considerations.

Matthias Wittkowski of EQT Private Equity highlighted the separation's role in establishing a market leader in the specialized CDMO space, emphasizing sustainability and future growth. Bespak's evolution represents a strategic response to regulatory and environmental pressures, aligning patient care with planetary health.